Optimizing manufacturing processes to develop novel cell and gene therapies

Cell & Gene Therapy Insights 2021; 7(5), 591–597


Published: 7 June 2021
Kerry Ingalls

Kerry Ingalls is Chief Operating Officer of Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure. He brings a long history of operating experience in pharmaceuticals and biotechnology. He has held numerous leadership roles including the oversight of clinical and commercial manufacturing for Amgen, leading its corporate engineering and then biologics manufacturing operations in Colorado, Ireland, California, and Puerto Rico. Ingalls has extensive professional background and training in the United States Navy spanning 30 years, including advising senior defense leaders on critical national security issues and leading elite deployed submarine operations. He received a Master of Arts in International Law and Diplomacy from Tufts University as well as a Bachelor of Science in Mechanical Engineering from the United States Naval Academy.